Advisory Council April 2016 Meeting Presentation: Research Federal Update



Friday, April 29, 2016


NAPA Research Progress Report

Richard J. Hodes, M.D.
National Institute on Aging

FY16 Budget Status -- Funding Increases Across the Board

  • $32 Billion for the NIH
    • $200M for PMI
    • $85M for BRAIN
    • $350M for AD
    • $1.6B for the NIA
      • ~4 percent increases across all ICs (not counting the $$ above) -- 4.2% for the NIA
      • All divisions will benefit
        • DBSR
        • DGCG
        • DAB
        • DN

NIA Appropriations FY 2005-2017 PB

Current versus Constant, FY05 Base Year
Line chart; data table below figure.
  06 07 08 09 10 11 12 13 14 15 16 17
(red line)
1,036.6 1,045.5 1,051.0 1,079.0 1,108.2 1,100.4 1,121.3 1,040.6 1,171.7 1,197.5 1,598.2 1,598.2
(blue line)
988.9 957.7 913.3 906.4 897.6 859.4 861.2 779.4 851.8 844.2 1,090.0 1,051.6
  • Difference from FY2006
  • In Current Dollars: $561.6M Increase
  • In Constant Dollars: $62.7M Increase
  • 6.3% increase FY06-FY17

NIA Appropriations

Bar chart.

Implementation of Additional AD Funding

  • Ten FOAs were released by the NIA in October 2015 for potential funding beginning in FY2016
  • NINDS has begun to release additional Alzheimer's Disease Related Dementias funding announcements
  • NIA is working with other NIH Institutes and Centers to help support relevant projects (beyond their IC paylines)

Application Update

  • NIA has received just under 300 applications for the first two submission deadlines eligible for FY2016 funding consideration for the 10 new AD FOAs.
  • These new submissions are in addition to the many applications targeting AD research submitted through normal investigator-initiated routes that NIA normally receives.

Payline Update

Requested Direct Costs <500k 500k or greater
Allocation General AD research General AD research
All applications except N.I. or E.S.I. R01s 9% 22% 6% 19%
N.I. R01s 17% 25% 14% 22%
E.S.I. R01s 19% 27% 16% 24%

FY17 AD Initiatives

  • Alzheimer's Disease Clinical Trials Consortium
  • Impact of Aging in Human Cell Models of AD
  • Neurodegenerative Disease Biorepository
  • From Association to Function in the AD Post-Genomics Era
  • Technology to Assess Everyday Functions

Tracking and Next Steps

  • RCDC has reported FY2015 dollars for AD+ADRD (in addition to the individual categories) and will do so going forward
  • This number will serve as a new baseline for tracking expenditures related to implementation of AD and related dementias research milestones
  • IADRP will continue to offer detailed tracking of initiatives and awards with respect to our research milestones, under the CADRO categories
  • NIH's FY17 plans will be revised operationally in the context of the new funding, as part of an ongoing planning and implementation process
  • The FY18 bypass budget is anticipated to be released in summer 2016

International Alzheimer's Disease Research Portfolio - UPDATE

  • Joint initiative led by NIA and the Alzheimer's Association (since 2010) to capture funded AD and related dementias research -- promotes collaboration
  • Currently includes 35 public, private and international funding organizations in 10 countries, including U.S., Australia, Brazil, Canada, Czech Republic, France, Italy, The Netherlands, Poland and the UK
    • Recent additions -- Research Manitoba (Canada), Bright Focus Foundation (US), LECMA: Vaincre Alzheimer (France), Internationale Stichting Alzheimer Onderzoek (The Netherlands)
  • Captures 7000+ unique projects conducted by 4000+ researchers across 1000+ institutions representing ~$4.7 billion in basic, translational and health services research funding
  • Upcoming plans -- update CADRO categories, topics and themes; solicit funded ADRD projects from IADRP and potential new partners.

AD Research Milestone Database

  • Web-based tool for tracking funding initiatives and activities developed by the NIH and other AD funding organizations aimed at addressing the research milestones associated with NAPA
  • Will facilitate strategic coordination and collaborations
  • Milestones tracked span the entire AD research landscape including basic, translational, clinical and health services research (the new ADRD milestones will be included once approved)

The FY2018 AD Bypass Budget -- In Progress

  • 2012 Alzheimer's Disease Research Summit
  • 2013 meeting on Alzheimer's Disease-Related Dementias: Research Challenges and Opportunities
  • 2013 meeting on Advancing Treatment for Alzheimer's Disease in Individuals with Down Syndrome
  • 2015 Alzheimer's Disease Research Summit
  • 2016 meeting on Alzheimer's Disease-Related Dementias*

The recommendations and milestones that emerged from these meetings are used to create a comprehensive and up-to-date set of milestones for the budgeting process

*The preliminary report from the 2016 ADRD meeting will be used for the FY18 Bypass Budget.

Combined External and Internal Input -- FY18 AD Bypass Budget

  • Input at 2012-2016 meetings:
    • Academic research community
    • Industry
    • Non-governmental organizations
  • Other Input:
    • 2016 Request for Information

Development of comprehensive milestones (NIH staff) -- based on recommendations and milestones from meetings

Trans-NIH (including NINDS) staff discussion; milestones edited to ensure comprehensive inclusion of priorities for FY18

NIH staff "price" the milestones

Final budget estimate for FY18

Molecular Mechanisms of the Vascular Etiology of Alzheimer's Consortium

  • NIA and NINDS launched M2OVE-AD in March 2016
  • The goal: to dissect the complex molecular mechanisms by which vascular risk factors influence AD and identify new targets for treatment and prevention.
  • It builds upon the open-science approach and the big-data infrastructure established by the Accelerating Medicines Partnership.
  • This five-year, $30-million program brings together >12 research teams working on five complementary projects.

Incidence of Dementia over Three Decades in the Framingham Heart Study

Screen shot of article cover.
The 5-year age-/sex-adjusted cumulative hazard rates for dementia were:
  • 3.6/100 persons -- 1st epoch (late '70s - early '80s)
  • 2.8/100 persons -- 2nd epoch (late '80s - early '90s)
  • 2.2/100 persons -- 3rd epoch (late '90s - early '00s)
  • 2.0/100 persons -- 4th epoch (late '00s - early '10s)
Relative to the incidence during the first epoch, incidence declined by 22%, 38%, and 44% during the 2nd, 3rd, and 4th epochs
Satizabal, CL et al. (2016) 374(6):523-32

VA Research Update

  • VA's Research office updated the wording in its specialty Alzheimer's Disease Request for Applications for biomedical laboratory or clinical research to include FTD, LBD, and/or vascular contributions to cognitive impairment and dementia in addition to AD
  • VA's Research office is discussing with NIA ways to increase collaboration on funding opportunities, including identifying opportunities to collaborate more closely around dementia research (e.g., recruitment/retention in clinical trials; data sharing; biorepository use; use of VA's electronic health records in research studies).

Return to

National Alzheimer's Project Act Home Page

Advisory Council on Alzheimer's Research, Care, and Services Page

Advisory Council on Alzheimer's Research, Care, and Services Meetings Page


"Mtg20-Slides8c.pdf" (pdf, 1.36Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®